Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.
Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.
The US and Europe have reached the same conclusion in more than 90% of marketing authorisation decisions for new medicines, according to a report from the European Medicines Agency.
The US Court of Appeals for the Federal Circuit yesterday, August 15, blocked Actavis’s attempt to market a generic version of Nalpropion Pharmaceuticals’ weight-loss drug Contrave.
Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.
Ireland-based Jazz Pharma has acquired Virginia-based Cavion in a deal that values the clinical-stage biotech company at up to $312.5 million.
Sandoz has confirmed that it plans to appeal against a decision that upheld the validity of two of Amgen’s patents for its arthritis treatment Enbrel, effectively blocking the launch of Sandoz’s biosimilar version.
The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.
Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
The US Federal Trade Commission is requiring medical device maker Boston Scientific to divest business, as part of a settlement resolving antitrust charges related to its acquisition of UK-based healthcare company BTG.